Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Liabilities and Shareholders Equity: 2022-2024

Historic Liabilities and Shareholders Equity for Immunocore Holdings (IMCR) over the last 3 years, with Dec 2024 value amounting to $1.0 billion.

  • Immunocore Holdings' Liabilities and Shareholders Equity rose 1.65% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 14.15%. This contributed to the annual value of $1.0 billion for FY2024, which is 69.10% up from last year.
  • As of FY2024, Immunocore Holdings' Liabilities and Shareholders Equity stood at $1.0 billion, which was up 69.10% from $597.0 million recorded in FY2023.
  • In the past 5 years, Immunocore Holdings' Liabilities and Shareholders Equity ranged from a high of $1.0 billion in FY2024 and a low of $526.8 million during FY2022.
  • In the last 3 years, Immunocore Holdings' Liabilities and Shareholders Equity had a median value of $597.0 million in 2023 and averaged $711.1 million.
  • Data for Immunocore Holdings' Liabilities and Shareholders Equity shows a peak YoY spiked of 69.10% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Immunocore Holdings' Liabilities and Shareholders Equity stood at $526.8 million in 2022, then rose by 13.33% to $597.0 million in 2023, then skyrocketed by 69.10% to $1.0 billion in 2024.